The early October announcement that Pfizer Inc. was to acquire DNA-vaccines firm PowderMed Ltd. no doubt lifted the spirits of the private biotech's backers, and underscored Big Pharma's rush to spread their bets on the next generation of large-molecule platforms. [See Deal]
Although PowderMed executives and investors refused to provide financial details about the transaction—sources directly affiliated with the companies would not...
Welcome to Scrip
Create an account to read this article
Already a subscriber?